GlaxoSmithKline Pakistan (KAR:GLAXO) Inventories, Finished Goods: ₨12,907 Mil (As of Mar. 2026)


KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
93 GF Score
Price ₨373.01
GF Value ₨323.95
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Inventories, Finished Goods?

GlaxoSmithKline Pakistan KAR:GLAXO +0.75% 93 Inventories, Finished Goods is ₨12,907 Mil as of Mar. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨323.95 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GlaxoSmithKline Pakistan's quarterly finished goods declined from Sep. 2025 (₨17,372 Mil) to Dec. 2025 (₨6,733 Mil) but then increased from Dec. 2025 (₨6,733 Mil) to Mar. 2026 (₨12,907 Mil).

GlaxoSmithKline Pakistan's annual finished goods increased from Dec. 2023 (₨6,354 Mil) to Dec. 2024 (₨6,406 Mil) and increased from Dec. 2024 (₨6,406 Mil) to Dec. 2025 (₨6,733 Mil).

GlaxoSmithKline Pakistan Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan Inventories, Finished Goods Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,394.17 5,099.72 6,354.33 6,406.24 6,732.70

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,538.22 7,302.27 17,371.92 6,732.70 12,906.77
KAR:GLAXO
93GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of ₨12,907 Mil mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Inventories, Finished Goods of ₨12,907 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's Inventories, Finished Goods too high?
GlaxoSmithKline Pakistan's current Inventories, Finished Goods is ₨12,907 Mil. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Inventories, Finished Goods compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Inventories, Finished Goods of ₨12,907 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Inventories, Finished Goods is ₨12,907 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨323.95, compared to a current price of ₨373.01 — trading 15.1% above its estimated fair value. The current Inventories, Finished Goods is ₨12,907 Mil. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Inventories, Finished Goods is ₨12,907 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨373.01 is trading 15.1% above its estimated GF Value™ of ₨323.95. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • Inventories, Finished Goods: ₨12,907 Mil
  • GF Value™: ₨323.95 vs. price of ₨373.01 (15.1% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score

Get the complete analysis for KAR:GLAXO

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨373.01
Price
₨323.95
GF Value